SCHEDULE 13G 0002038499 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 10/07/2025 0001615219 Salarius Pharmaceuticals, Inc. 79400X503 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 Rule 13d-1(c) C/M Capital Master Fund, LP DE 0.00 0.00 0.00 0.00 0.00 N 0 PN C/M CAPITAL PARTNERS, LP DE 0.00 0.00 0.00 0.00 0.00 N 0 PN Thomas Walsh X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Jonathan Juchno X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X, Houston, TX 77021 This statement is filed by: (i) C/M Capital Master Fund, LP, a Delaware limited partnership ("C/M Master Fund"); (ii) C/M Capital Partners, LP, a Delaware limited partnership ("C/M Capital Partners"); (iii) Thomas Walsh ("Mr. Walsh"); and (iv) Jonathan Juchno ("Mr. Juchno"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The shares of common stock, par value $0.0001 per share (the "Common Stock") of Salarius Pharmaceuticals, Inc. to which this filing relates were held by C/M Master Fund. C/M Capital Partners is the investment manager to C/M Master Fund. Messrs. Walsh and Juchno are the managing members of the general partner of C/M Capital Partners. Messrs. Walsh and Juchno disclaim beneficial ownership of any shares of Common Stock that were held by C/M Master Fund. The address of the business office of each of the Reporting Persons is 1111 Brickell Ave, Suite 2920, Miami, FL 33131. Each of C/M Master Fund and C/M Capital Partners is a limited partnership organized under the laws of the State of Delaware. Each of Messrs. Walsh and Juchno is a citizen of the United States. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. As of the date of the event which requires the filing of this Schedule 13G, the Reporting Persons may have been deemed to beneficially own more than 5% of the shares of Common Stock outstanding. 0% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement C/M Capital Master Fund, LP /s/ Thomas Walsh 10/14/2025 C/M CAPITAL PARTNERS, LP /s/ Thomas Walsh 10/14/2025 Thomas Walsh /s/ Thomas Walsh 10/14/2025 Jonathan Juchno /s/ Jonathan Juchno 10/14/2025